An animal model of mitochondrial myopathy: a biochemical and physiological investigation of rats treated in vivo with the NADH-CoQ reductase inhibitor, diphenyleneiodonium

J Neurol Sci. 1988 Feb;83(2-3):335-47. doi: 10.1016/0022-510x(88)90079-2.

Abstract

Chronic administration of the NADH-CoQ reductase inhibitor, diphenyleneiodonium to rats at two dose levels, 1.0 and 1.5 mg/kg per day, caused a 40% and 60% reduction, respectively, in the in vitro rate of NAD-linked respiration by skeletal muscle mitochondria. At the highest dose, muscle fatigue, lactic acidosis and an over-utilization of phosphocreatine was observed in the gastrocnemius muscle during mild stimulation of 1 Hz frequency. The resynthesis of phosphocreatine following muscle stimulation was about 2 fold slower in the treated animal group. At the low dose, no significant biochemical changes were observed during muscle stimulation at 4 Hz. The results are discussed in terms of skeletal muscle "oxidative reserve", twitch tension maintenance and the relevance to the human diseased state of mitochondrial myopathy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acidosis / chemically induced
  • Animals
  • Dose-Response Relationship, Drug
  • Male
  • Mitochondria, Muscle / drug effects
  • Mitochondria, Muscle / pathology*
  • Muscles / drug effects
  • Muscles / metabolism
  • Muscles / pathology*
  • Muscular Diseases / chemically induced*
  • Muscular Diseases / metabolism
  • NAD(P)H Dehydrogenase (Quinone)
  • Onium Compounds / toxicity*
  • Phosphocreatine / metabolism
  • Quinone Reductases / metabolism*
  • Rats
  • Rats, Inbred Strains
  • Time Factors

Substances

  • Onium Compounds
  • Phosphocreatine
  • diphenyleneiodonium
  • NAD(P)H Dehydrogenase (Quinone)
  • Quinone Reductases